You are here

P&T News

April 18

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis

April 16

Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial

April 11

Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions
Drug Candidate May Prevent Virus From Fusing With Epithelial Cells, B Cells

April 9

Dovato Achieved Non-inferior Efficacy Compared to Traditional Regimen; No Cases of Resistance
Optogenetics Provides Insights Into Basis of Fear, Addiction
First Patient Expected to Receive AMT-130 Therapy in 2019

April 4

LAMA/LABA Population Expected to Grow Rapidly in Coming Years
Currently Incurable RRP Affects 20,000 Cases in the U.S.

April 2

Incurable Genetic Condition Affects One in 3-4,000 People
First-in-Human Phase 1 Trial Will Begin This Year
Aggressive T-cell Prolymphocytic Leukemia Has Very Limited Treatment Options
Approximately 250,000 People in the U.S. Live with PI

March 28

Subcutaneous Agent Could Prevent Laparoscopic Surgery, Emergency Surgery
Majority of Trial Patients Achieved Normal Testoserone Levels
Trial Showed Mayzent Reduced Disability Progression, Relapses 
Device Use Should Continue–Remote Monitoring Benefits Outweigh Cyberattack Risks

March 26

Patients With Implant Saw Improved Walking Distance